Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 08, 2024 16:06 ET
|
Context Therapeutics Inc.
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE...
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 02, 2024 07:31 ET
|
Context Therapeutics Inc.
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --...
Context Therapeutics Announces $100 Million Private Placement
May 02, 2024 07:30 ET
|
Context Therapeutics Inc.
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 ...
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
April 01, 2024 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
March 21, 2024 07:43 ET
|
Context Therapeutics Inc.
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into...
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023 16:15 ET
|
Context Therapeutics Inc.
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into...
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
October 31, 2023 09:00 ET
|
Context Therapeutics Inc.
CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product...
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023 09:00 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 09, 2023 16:10 ET
|
Context Therapeutics Inc.
Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for...
Context Therapeutics to Participate in Two August 2023 Investor Conferences
August 01, 2023 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living...